Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies

Key Inclusion Criteria:

- Diagnosis of B-cell iNHL, DLBCL, MCL, or CLL as documented by medical records and with
histology based on criteria established by the World Health Organization

- For institutions that have Phase 3 or Phase 4 protocols studying idelalisib (Zydelig®)
; individuals with malignancies being studied in these protocols must have failed
screening in the respective idelalisib protocol

- Prior treatment for lymphoid malignancy requiring treatment for progressive disease

- Presence of radiographically measurable lymphadenopathy or extranodal lymphoid
malignancy

- All acute toxic effects of any prior antitumor therapy resolved to Grade ≤ 1 before
the start of study drug

- Karnofsky performance status of ≥ 60

- Life expectancy of at least 3 months

Key Exclusion Criteria:

- Known histological transformation from iNHL or CLL to an aggressive form of
non-Hodgkin lymphoma (ie, Richter transformation) except if the CLL patient is
enrolling in the B-cell receptor (BCR) previously treated cohort

- Known active central nervous system or leptomeningeal lymphoma

- Presence of known intermediate- or high-grade myelodysplastic syndrome

- Evidence of ongoing systemic bacterial, fungal, or viral infection at the time of
start of study drug

- Ongoing liver injury

- Ongoing or recent hepatic encephalopathy

- Ongoing drug-induced pneumonitis

- Ongoing inflammatory bowel disease

- Ongoing alcohol or drug addiction

- Pregnancy or breastfeeding

- History of prior allogeneic bone marrow progenitor cell or solid organ transplantation

- Ongoing immunosuppressive therapy

- Concurrent participation in an investigational drug trial with therapeutic intent

NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.